XML 30 R77.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions, Collaboration, License and Other Strategic Agreements - Narrative (Details) - USD ($)
1 Months Ended 9 Months Ended 12 Months Ended 24 Months Ended
Jan. 16, 2019
Apr. 03, 2017
Jun. 30, 2019
Jun. 30, 2018
Feb. 28, 2017
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Dec. 31, 2017
Mar. 31, 2019
Sep. 30, 2017
Collaborative Agreements                      
Payment for debt extinguishment           $ 0 $ 28,054,000        
Endoceutics, Inc.                      
Collaborative Agreements                      
Consideration recorded                 $ 83,500,000    
Payments related to collaborative arrangement   $ 50,000,000.0                  
Number of shares issued under arrangement (in shares)   600,000                  
Net shares issued in connection with license agreement, value   $ 13,500,000                  
IPR&D expense                 5,800,000    
Palatin Technologies, Inc.                      
Collaborative Agreements                      
Payments related to collaborative arrangement         $ 60,000,000.0            
Out-of-pocket expenses (up to)         $ 25,000,000.0            
Intrarosa | Endoceutics, Inc.                      
Collaborative Agreements                      
Payments related to collaborative arrangement                   $ 6,000,000.0  
Out-of-pocket expenses (up to)                     $ 20,000,000.0
Intrarosa | Endoceutics, Inc. | Developed Technology Rights                      
Collaborative Agreements                      
Finite-lived intangible assets                 77,700,000    
Intrarosa | Endoceutics, Inc. | Delivery Of Intrarosa Launch Quantities                      
Collaborative Agreements                      
Payments related to collaborative arrangement                 $ 10,000,000.0    
Intrarosa | Endoceutics, Inc. | First Anniversary Of Closing                      
Collaborative Agreements                      
Payments related to collaborative arrangement               $ 10,000,000.0      
Vyleesi Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement, Acceptance by U.S.Food and Drug Administration of New Drug Application                      
Collaborative Agreements                      
Payments related to collaborative arrangement       $ 20,000,000.0              
Vyleesi Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement, U.S.Food And Drug Administration Approval                      
Collaborative Agreements                      
Payments related to collaborative arrangement     $ 60,000,000.0                
Failure To Supply A Certain Percentage Of Product | Prasco, LLC                      
Collaborative Agreements                      
Failure to supply, penalties           $ 3,500,000          
Perosphere Pharmaceuticals Inc.                      
Collaborative Agreements                      
Consideration recorded $ 50,000,000.0                    
Payments of asset acquisitions 40,000,000.0                    
Cancellation of convertible note 10,000,000.0                    
Other liabilities 6,200,000                    
Cash consideration $ 60,800,000                    
Discount rate 34.00%                    
Perosphere Pharmaceuticals Inc. | Perosphere Convertible Note | Convertible Debt                      
Collaborative Agreements                      
Aggregate principal amount of debt issued $ 10,000,000.0                    
Perosphere Pharmaceuticals Inc. | Perosphere Term Loan | Line of Credit                      
Collaborative Agreements                      
Payment for debt extinguishment $ 12,000,000.0